CPC C07D 471/04 (2013.01) [A61P 35/04 (2018.01); C07D 487/04 (2013.01); C07D 491/048 (2013.01); C07D 495/04 (2013.01); C07D 513/04 (2013.01)] | 7 Claims |
1. A method for treating breast cancer, melanoma, prostate cancer, colorectal cancer, or urotherial carcinoma, said method comprising administering to a subject in need thereof a compound having formula (III-4):
where:
either X1 is a nitrogen atom and X2 is a C(R4) group,
or X1 is a C(R5) group and X2 is a nitrogen atom,
or X1 and X2 are a nitrogen atom,
R4 and R5 each independently being H or a substituent selected from the group consisting of: halogen atoms, (C1-C6)(cyclo)alkyl groups, NRaRb groups, and ORa groups, Ra and Rb each independently being H or (C1-C6)alkyl group,
R1 is H, a (C1-C6)alkyl group or a radical selected from the group consisting of: —ORa, —NHRa, —NRaRb, —NH—C(═O)Ra, —C(═O)Ra, —C(═O)ORa, —NH—CN, —C(═O)NRaRb, Cl, F, CN and nitrogen-containing and/or oxygen-containing heterocycles, said nitrogen-containing heterocycles and/or said oxygen-containing heterocycles having 5 atoms, and wherein Ra and Rb each independently being H, a (C1-C6)alkyl group or (C3-C6)cycloalkyl group;
R2 and R3 are each independently H or a substituent selected from the group consisting of: halogen atoms, (C1-C6)(cyclo)alkyl groups, NRaRb groups, and ORa groups, Ra and Rb each independently being H or (C1-C6)alkyl group;
said compound of formula (III-4) being in pure stereoisomer form, or in the form of a mixture of enantiomers and/or diastereoisomers.
|